IntroductionThe biologics market remains the most dynamic area within psoriasis treatment. Stelara (ustekinumab; Janssen Biotech) is displaying impressive uptake in the US and EU, to the detriment of established brands. With Abbott withdrawing regulatory filings of Ozespa (briakinumab), a key contender to Stelara in early 2011, this leaves Stelara to continue its ascendance across the seven major markets.Features and benefits* Gain insight into how new market entrants are positioned in the treatment algorithm versus established drugs, and how this may change in the future.* Access Datamonitor's independent evaluation of prominent brands and pipeline agents for psoriasis, with physician perception of such therapies.* Enhance understanding of market dynamics, using Datamonitor's assessment of clinical and commercial attributes of marketed and pipeline therapies.* Review important clinical milestones of key late-stage pipeline candidates, with analysis of new clinical trial data.HighlightsDatamonitor's survey reveals that Stelara is gaining traction in moderate to severe patients at both first and second line and beyond, after 2 years in the US and EU markets. This is notable because typical first-line options Enbrel (etanercept) and Humira (adalimumab) have been available in these markets for 6 years and 4 years, respectively.Interest in interleukin (IL) targets in the dermatology community continues to escalate. AIN457 leads the way in IL-17 targeting therapies and with strong efficacy data demonstrated in Phase II, it emerges as a notable pipeline candidate in the IL class to watch in the future.Celgene's apremilast moved into Phase III in the US and EU during 2011. Still, late-stage data are needed, and it remains to be seen if it provides improved efficacy over established systemic drugs. This is vital because Pfizer's oral agent, tofacitinib, also in Phase III, has shown efficacy in line with leading brand Enbrel in Phase II trials.Your key questions answered* What impact could pipeline agents have on the future treatment of psoriasis, should they gain clinical and commercial success'* What are the comparative strengths and weaknesses of the key psoriasis products and pipeline therapies'* How do pipeline agents stack up against accepted gold-standard drugs in terms of their ability to meet clinical unmet needs in psoriasis treatment'* To what extent could novel oral agents such as tofacitinib (CP-690,550; Pfizer) and apremilast (CC-10004; Celgene) challenge biologic brands'* Will any products challenge Leo Pharma's dominance in the psoriasis topical market segment'

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Product Profiles: Psoriasis ' Novel therapies raise the bar for
biologics
Published on November 2011
Report Summary
Introduction
The biologics market remains the most dynamic area within psoriasis treatment. Stelara (ustekinumab; Janssen Biotech) is displaying
impressive uptake in the US and EU, to the detriment of established brands. With Abbott withdrawing regulatory filings of Ozespa
(briakinumab), a key contender to Stelara in early 2011, this leaves Stelara to continue its ascendance across the seven major
markets.
Features and benefits
* Gain insight into how new market entrants are positioned in the treatment algorithm versus established drugs, and how this may
change in the future.
* Access Datamonitor's independent evaluation of prominent brands and pipeline agents for psoriasis, with physician perception of
such therapies.
* Enhance understanding of market dynamics, using Datamonitor's assessment of clinical and commercial attributes of marketed and
pipeline therapies.
* Review important clinical milestones of key late-stage pipeline candidates, with analysis of new clinical trial data.
Highlights
Datamonitor's survey reveals that Stelara is gaining traction in moderate to severe patients at both first and second line and beyond,
after 2 years in the US and EU markets. This is notable because typical first-line options Enbrel (etanercept) and Humira
(adalimumab) have been available in these markets for 6 years and 4 years, respectively.
Interest in interleukin (IL) targets in the dermatology community continues to escalate. AIN457 leads the way in IL-17 targeting
therapies and with strong efficacy data demonstrated in Phase II, it emerges as a notable pipeline candidate in the IL class to watch in
the future.
Celgene's apremilast moved into Phase III in the US and EU during 2011. Still, late-stage data are needed, and it remains to be seen
if it provides improved efficacy over established systemic drugs. This is vital because Pfizer's oral agent, tofacitinib, also in Phase III,
has shown efficacy in line with leading brand Enbrel in Phase II trials.
Your key questions answered
* What impact could pipeline agents have on the future treatment of psoriasis, should they gain clinical and commercial success'
* What are the comparative strengths and weaknesses of the key psoriasis products and pipeline therapies'
* How do pipeline agents stack up against accepted gold-standard drugs in terms of their ability to meet clinical unmet needs in
psoriasis treatment'
* To what extent could novel oral agents such as tofacitinib (CP-690,550; Pfizer) and apremilast (CC-10004; Celgene) challenge
biologic brands'
* Will any products challenge Leo Pharma's dominance in the psoriasis topical market segment'
Product Profiles: Psoriasis ' Novel therapies raise the bar for biologics (From Slideshare) Page 1/6

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Table of Content
OVERVIEW
Catalyst
Summary
MARKET DEFINITION AND OVERVIEW
Product overview
MARKETED PRODUCT PROFILES
Enbrel (etanercept; Amgen/Pfizer/Stiefel/Takeda)
Drug profile
Development overview
SWOT analysis
Product positioning
Physician perception of Enbrel
Clinical and commercial attractiveness
Humira (adalimumab; Abbott/Eisai)
Drug profile
Development overview
SWOT analysis
Product positioning
Physician perception of Humira
Clinical and commercial attractiveness
Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe)
Drug profile
Development overview
SWOT analysis
Product positioning
Physician perception of Remicade
Clinical and commercial attractiveness
Stelara (ustekinumab; Janssen Biotech/Janssen-Cilag/Johnson & Johnson)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Dovonex (calcipotriol; Leo Pharma/Intendis/Torii/Teikoku Medix)
Drug profile
Development overview
Product positioning
Physician perception of Dovonex
Clinical and commercial attractiveness
Dovobet (calcipotriol/betamethasone; Leo Pharma/Intendis)
Drug profile
Development overview
SWOT analysis
Product positioning
Product Profiles: Psoriasis ' Novel therapies raise the bar for biologics (From Slideshare) Page 2/6

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Clinical and commercial attractiveness
Silkis/Vectical (calcitriol; Galderma)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Other marketed drugs for psoriasis
Amevive (alefacept; Astellas/Dompe)
Product positioning
Sorilux (calcipotriene foam/U0267; GlaxoSmithKline/Stiefel)
Product positioning
PIPELINE PRODUCT PROFILES
Ozespa (briakinumab/ABT-874; Abbott)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
AIN457 (secukinumab; Novartis)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Physician perception
Clinical and commercial attractiveness
Tofacitinib (formerly tasocitinib/CP-690,550; Pfizer)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Physician perception
Clinical and commercial attractiveness
Apremilast (CC-10004; Celgene)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Physician perception
Clinical and commercial attractiveness
Other drugs in development for psoriasis
Voclosporin (ISA247; Isotechnika)
Development overview
BIBLIOGRAPHY
Journal papers
Websites
Datamonitor reports
APPENDIX A ' SURVEY INFORMATION
Product Profiles: Psoriasis ' Novel therapies raise the bar for biologics (From Slideshare) Page 3/6

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Physician research methodology 2011
The 2011 survey questionnaire
Physician research methodology 2009
The 2009 survey questionnaire
Physician perception of select brands 2009
APPENDIX B
Contributing experts
Datamonitor drug assessment scorecard methodology
Report methodology
Product Profiles: Psoriasis ' Novel therapies raise the bar for biologics (From Slideshare) Page 4/6

5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Product Profiles: Psoriasis ' Novel therapies raise the bar for biologics
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 11 400.00 Quantity: _____
Corporate License--USD 28 500.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Product Profiles: Psoriasis ' Novel therapies raise the bar for biologics (From Slideshare) Page 5/6

6. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Product Profiles: Psoriasis ' Novel therapies raise the bar for biologics (From Slideshare) Page 6/6